Cargando…
Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software
Objective: To investigate two commercial software and their efficacy in the assessment of chest CT sequelae in patients affected by COVID-19 pneumonia, comparing the consistency of tools. Materials and Methods: Included in the study group were 120 COVID-19 patients (56 women and 104 men; 61 years of...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623042/ https://www.ncbi.nlm.nih.gov/pubmed/34834455 http://dx.doi.org/10.3390/jpm11111103 |
_version_ | 1784605836897681408 |
---|---|
author | Granata, Vincenza Ianniello, Stefania Fusco, Roberta Urraro, Fabrizio Pupo, Davide Magliocchetti, Simona Albarello, Fabrizio Campioni, Paolo Cristofaro, Massimo Di Stefano, Federica Fusco, Nicoletta Petrone, Ada Schininà, Vincenzo Villanacci, Alberta Grassi, Francesca Grassi, Roberta Grassi, Roberto |
author_facet | Granata, Vincenza Ianniello, Stefania Fusco, Roberta Urraro, Fabrizio Pupo, Davide Magliocchetti, Simona Albarello, Fabrizio Campioni, Paolo Cristofaro, Massimo Di Stefano, Federica Fusco, Nicoletta Petrone, Ada Schininà, Vincenzo Villanacci, Alberta Grassi, Francesca Grassi, Roberta Grassi, Roberto |
author_sort | Granata, Vincenza |
collection | PubMed |
description | Objective: To investigate two commercial software and their efficacy in the assessment of chest CT sequelae in patients affected by COVID-19 pneumonia, comparing the consistency of tools. Materials and Methods: Included in the study group were 120 COVID-19 patients (56 women and 104 men; 61 years of median age; range: 21–93 years) who underwent chest CT examinations at discharge between 5 March 2020 and 15 March 2021 and again at a follow-up time (3 months; range 30–237 days). A qualitative assessment by expert radiologists in the infectious disease field (experience of at least 5 years) was performed, and a quantitative evaluation using thoracic VCAR software (GE Healthcare, Chicago, Illinois, United States) and a pneumonia module of ANKE ASG-340 CT workstation (HTS Med & Anke, Naples, Italy) was performed. The qualitative evaluation included the presence of ground glass opacities (GGOs) consolidation, interlobular septal thickening, fibrotic-like changes (reticular pattern and/or honeycombing), bronchiectasis, air bronchogram, bronchial wall thickening, pulmonary nodules surrounded by GGOs, pleural and pericardial effusion, lymphadenopathy, and emphysema. A quantitative evaluation included the measurements of GGOs, consolidations, emphysema, residual healthy parenchyma, and total lung volumes for the right and left lung. A chi-square test and non-parametric test were utilized to verify the differences between groups. Correlation coefficients were used to analyze the correlation and variability among quantitative measurements by different computer tools. A receiver operating characteristic (ROC) analysis was performed. Results: The correlation coefficients showed great variability among the quantitative measurements by different tools when calculated on baseline CT scans and considering all patients. Instead, a good correlation (≥0.6) was obtained for the quantitative GGO, as well as the consolidation volumes obtained by two tools when calculated on baseline CT scans, considering the control group. An excellent correlation (≥0.75) was obtained for the quantitative residual healthy lung parenchyma volume, GGO, consolidation volumes obtained by two tools when calculated on follow-up CT scans, and for residual healthy lung parenchyma and GGO quantification when the percentage change of these volumes were calculated between a baseline and follow-up scan. The highest value of accuracy to identify patients with RT-PCR positive compared to the control group was obtained by a GGO total volume quantification by thoracic VCAR (accuracy = 0.75). Conclusions: Computer aided quantification could be an easy and feasible way to assess chest CT sequelae due to COVID-19 pneumonia; however, a great variability among measurements provided by different tools should be considered. |
format | Online Article Text |
id | pubmed-8623042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86230422021-11-27 Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software Granata, Vincenza Ianniello, Stefania Fusco, Roberta Urraro, Fabrizio Pupo, Davide Magliocchetti, Simona Albarello, Fabrizio Campioni, Paolo Cristofaro, Massimo Di Stefano, Federica Fusco, Nicoletta Petrone, Ada Schininà, Vincenzo Villanacci, Alberta Grassi, Francesca Grassi, Roberta Grassi, Roberto J Pers Med Article Objective: To investigate two commercial software and their efficacy in the assessment of chest CT sequelae in patients affected by COVID-19 pneumonia, comparing the consistency of tools. Materials and Methods: Included in the study group were 120 COVID-19 patients (56 women and 104 men; 61 years of median age; range: 21–93 years) who underwent chest CT examinations at discharge between 5 March 2020 and 15 March 2021 and again at a follow-up time (3 months; range 30–237 days). A qualitative assessment by expert radiologists in the infectious disease field (experience of at least 5 years) was performed, and a quantitative evaluation using thoracic VCAR software (GE Healthcare, Chicago, Illinois, United States) and a pneumonia module of ANKE ASG-340 CT workstation (HTS Med & Anke, Naples, Italy) was performed. The qualitative evaluation included the presence of ground glass opacities (GGOs) consolidation, interlobular septal thickening, fibrotic-like changes (reticular pattern and/or honeycombing), bronchiectasis, air bronchogram, bronchial wall thickening, pulmonary nodules surrounded by GGOs, pleural and pericardial effusion, lymphadenopathy, and emphysema. A quantitative evaluation included the measurements of GGOs, consolidations, emphysema, residual healthy parenchyma, and total lung volumes for the right and left lung. A chi-square test and non-parametric test were utilized to verify the differences between groups. Correlation coefficients were used to analyze the correlation and variability among quantitative measurements by different computer tools. A receiver operating characteristic (ROC) analysis was performed. Results: The correlation coefficients showed great variability among the quantitative measurements by different tools when calculated on baseline CT scans and considering all patients. Instead, a good correlation (≥0.6) was obtained for the quantitative GGO, as well as the consolidation volumes obtained by two tools when calculated on baseline CT scans, considering the control group. An excellent correlation (≥0.75) was obtained for the quantitative residual healthy lung parenchyma volume, GGO, consolidation volumes obtained by two tools when calculated on follow-up CT scans, and for residual healthy lung parenchyma and GGO quantification when the percentage change of these volumes were calculated between a baseline and follow-up scan. The highest value of accuracy to identify patients with RT-PCR positive compared to the control group was obtained by a GGO total volume quantification by thoracic VCAR (accuracy = 0.75). Conclusions: Computer aided quantification could be an easy and feasible way to assess chest CT sequelae due to COVID-19 pneumonia; however, a great variability among measurements provided by different tools should be considered. MDPI 2021-10-28 /pmc/articles/PMC8623042/ /pubmed/34834455 http://dx.doi.org/10.3390/jpm11111103 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Granata, Vincenza Ianniello, Stefania Fusco, Roberta Urraro, Fabrizio Pupo, Davide Magliocchetti, Simona Albarello, Fabrizio Campioni, Paolo Cristofaro, Massimo Di Stefano, Federica Fusco, Nicoletta Petrone, Ada Schininà, Vincenzo Villanacci, Alberta Grassi, Francesca Grassi, Roberta Grassi, Roberto Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title | Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title_full | Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title_fullStr | Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title_full_unstemmed | Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title_short | Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software |
title_sort | quantitative analysis of residual covid-19 lung ct features: consistency among two commercial software |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623042/ https://www.ncbi.nlm.nih.gov/pubmed/34834455 http://dx.doi.org/10.3390/jpm11111103 |
work_keys_str_mv | AT granatavincenza quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT ianniellostefania quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT fuscoroberta quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT urrarofabrizio quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT pupodavide quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT magliocchettisimona quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT albarellofabrizio quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT campionipaolo quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT cristofaromassimo quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT distefanofederica quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT fusconicoletta quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT petroneada quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT schininavincenzo quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT villanaccialberta quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT grassifrancesca quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT grassiroberta quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware AT grassiroberto quantitativeanalysisofresidualcovid19lungctfeaturesconsistencyamongtwocommercialsoftware |